News

Alexander vos 1x

Alexander Vos Appointed Chairman of Scenic Biotech’s Board of Directors

Scenic Biotech Appoints Industry Veteran Ben Machielse to Board of Directors

Scenic Biotech enters into Research Collaboration with Bristol Myers Squibb

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882

Drug target review@4x

Scenic’s Vincent Blomen in Drug Target Review

Scenic Biotech Enters Cooperative Research and Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease

Scenic Biotech Strengthens Drug Discovery Expertise in Management Team with the Addition of Kristof Van Emelen

Scenic Biotech Appoints Jens Würthner as Chief Medical Officer

Picture website

Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to Find Tailored Treatment for the Complex Rare Disease

1. scenic biotech genetic modifier image 1

Proof of concept in preclinical models for the use of QPCTL inhibition

Rene van den oever

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

Genbanner ecp green i

Biocentury features an emerging company profile on Scenic Biotech